Infinity Pharmaceuticals Inc
NASDAQ:INFI
Intrinsic Value
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. [ Read More ]
The intrinsic value of one
INFI
stock under the Base Case scenario is
0.4364
USD.
Compared to the current market price of 0.0037 USD,
Infinity Pharmaceuticals Inc
is
Undervalued by 99%.
INFI's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
INFI or that its price is influenced by factors unrelated to fundamentals.
Infinity Pharmaceuticals Inc's market capitalization is 335.8k USD.
INFI stock price is 0.0037 USD.
INFI stock price (0.0037 USD) is 99% less than its Intrinsic Value (0.4364 USD).
INFI. Open DCF Valuation
INFI stock price (0.0037 USD) is 99% less than its Relative Value (0.4364 USD). Open Relative Valuation
INFI.
INFI's Revenue has grown by 16% over the past 12 months.
INFI's short-term assets (20m USD) exceed its short-term liabilties (12m USD).
INFI's Revenue has been growing by an exceptional 22% per year for the last 3 years.
INFI's ROE (Return on Equity) has significantly increased in the last 3 years from -166% to 213%.
INFI's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -814% to -1 542%, and is approaching profitability.
INFI has positive Gross Profit for the last twelve months.
INFI has negative Operating Income for the last twelve months.
INFI has negative Net Income for the last twelve months.
INFI's ROE (Return on Equity) for the past 12 months is very high and is equal to 213%.
INFI's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 542%.
INFI has negative three-year average ROE (Return on Equity): -4%. The company is not efficient at transforming stockholders' equity into net income.
INFI's long-term liabilties (59m USD) exceed its long-term assets (21m USD).
INFI has negative Free Cash Flow for the last twelve months.
INFI has negative three-year average ROIC (Return on Invested Capital): -1 762%. The company is not efficient at using invested capital to generate operating income.
INFI's D/E (Debt to Equity) is very low and is equal to 0.
INFI's Altman Z-Score is very low and is equal to -64.6.
Fundamental Analysis
Infinity Pharmaceuticals Inc
Balance Sheet Decomposition
Infinity Pharmaceuticals Inc
| Current Assets | 19.9m |
| Cash & Short-Term Investments | 17.7m |
| Other Current Assets | 2.2m |
| Non-Current Assets | 1.3m |
| PP&E | 1.1m |
| Other Non-Current Assets | 242k |
| Current Liabilities | 12.1m |
| Accounts Payable | 1.5m |
| Accrued Liabilities | 10.6m |
| Non-Current Liabilities | 46.6m |
| Other Non-Current Liabilities | 46.6m |
Earnings Waterfall
Infinity Pharmaceuticals Inc
|
Revenue
|
2.6m
USD
|
|
Cost of Revenue
|
-1.5m
USD
|
|
Gross Profit
|
1m
USD
|
|
Operating Expenses
|
-43.1m
USD
|
|
Operating Income
|
-42m
USD
|
|
Other Expenses
|
1.1m
USD
|
|
Net Income
|
-40.9m
USD
|
Free Cash Flow Analysis
Infinity Pharmaceuticals Inc
What is Free Cash Flow?
INFI Profitability Score
Profitability Due Diligence
Infinity Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Infinity Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
INFI Solvency Score
Solvency Due Diligence
Infinity Pharmaceuticals Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Infinity Pharmaceuticals Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INFI Price Targets Summary
Infinity Pharmaceuticals Inc
Ownership
INFI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
INFI Price
Infinity Pharmaceuticals Inc
| Average Annual Return | 25.33% |
| Standard Deviation of Annual Returns | 64.75% |
| Max Drawdown | -100% |
| Market Capitalization | 335.8k USD |
| Shares Outstanding | 89 904 800 |
| Percentage of Shares Shorted | 2.47% |
Company Profile
Infinity Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.
You don't have any saved screeners yet
